New Insights Into Hepatic Impairment (HI) Trials
ABSTRACT Hepatic impairment (HI) trials are traditionally part of the clinical pharmacology development to assess the need for dose adaptation in people with impaired metabolic capacity due to their diseased liver. This review aimed at looking into the data from dedicated HI studies, cluster these d...
Saved in:
| Main Authors: | Sebastian Haertter, Maximilian Lobmeyer, Brian C. Ferslew, Pallabi Mitra, Thomas Arnhold |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/cts.70130 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Hepatic Impairment on the Pharmacokinetics of Baicalin in Rats: Critical Roles of Gut Microbiota and Hepatic Transporters
by: Ping Li, et al.
Published: (2025-06-01) -
Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies
by: Megumi Iwai, et al.
Published: (2025-08-01) -
Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose–response relationships
by: Nicolas Simon, et al.
Published: (2025-07-01) -
Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open‐Label, Parallel‐Group, Single‐Center Studies
by: Annalisa Piccinno, et al.
Published: (2025-05-01) -
Preclinical pharmacokinetics and in vitro ADME properties of PAT-1102: a novel HDAC inhibitor for cancer therapy
by: Chandrashekar Mataguru Doreswamy, et al.
Published: (2025-05-01)